- Research article
- Open Access
- Open Peer Review
Effects of Eleutheroside B and Eleutheroside E on activity of cytochrome P450 in rat liver microsomes
© Guo et al.; licensee BioMed Central Ltd. 2014
- Received: 16 July 2013
- Accepted: 13 December 2013
- Published: 2 January 2014
Chemicals of herbal products may cause unexpected toxicity or adverse effect by the potential for alteration of the activity of CYP450 when co-administered with other drugs. Eleutherococcus senticosus (ES), has been widely used as a traditional herbal medicine and popular herbal dietary supplements, and often co-administered with many other drugs. The main bioactive constituents of ES were considered to be eleutherosides including eleutheroside B (EB) and eleutheroside E (EE). This study was to investigate the effects of EB and EE on CYP2C9, CYP2D6, CYP2E1 and CYP3A4 in rat liver microsomes in vitro.
Probe drugs of tolbutamide (TB), dextromethorphan (DM), chlorzoxazone (CLZ) and testosterone (TS) as well as eleutherosides of different concentrations were added to incubation systems of rat liver microsomes in vitro. After incubation, validated HPLC methods were used to quantify relevant metabolites.
The results suggested that EB and EE exhibited weak inhibition against the activity of CYP2C9 and CYP2E1, but no effects on CYP2D6 and CYP3A4 activity. The IC50 values for EB and EE were calculated to be 193.20 μM and 188.36 μM for CYP2E1, 595.66 μM and 261.82 μM for CYP2C9, respectively. Kinetic analysis showed that inhibitions of CYP2E1 by EB and EE were best fit to mixed-type with Ki value of 183.95 μM and 171.63 μM, respectively.
These results indicate that EB and EE may inhibit the metabolism of drugs metabolized via CYP2C9 and CYP2E1, and have the potential to increase the toxicity of the drugs.
- Eleutheroside B
- Eleutheroside E
- Cytochrome P450
- In vitro
Cytochrome P450 (CYP450), the most important drug-metabolizing enzymes, with largest number and highest abundance of CYP isoforms present in the liver. It is well known that CYP450 play a vital role in the metabolism of currently used drugs. Most drugs are metabolized through several major CYP isoforms. CYP3A4, CYP2D6, CYP2C9 and CYP2E1 have been estimated to be involved in the metabolism of approximately 85% of the drugs in clinical practice . Since these subtypes metabolize numerous drugs, drug-drug interactions (DDIs) can potentially occur when multiple drugs are co-administered. Therefore, evaluation of effects on CYP isoforms of drugs is important for the prediction of potential DDIs. Inhibition of CYP450 enzymes is the most important reason caused DDIs, which raises the toxicity of drugs.
To our knowledge, this is the first study focus on the potential role of EB and EE in CYP450-mediated DDIs. The present study was performed to investigate the influence of EB and EE on the activities of CYP2C9, CYP2D6, CYP2E1 and CYP3A4 in rat liver microsomes and the mechanisms in vitro, which could be used to predict the probability of herb-drug interactions, providing references for correlation studies and decrease the risk of drug use.
Chemicals and reagents
Tolbutamide was purchased from Dr. Ehrenstorfer GmbH (Augsburg, Germany). 4-hydroxytolbutamide and 6-hydroxychlorzoxazone were obtained from Toronto Research Chemicals Inc. (North York, Canada). Dextromethorphan, dextrorphan and chlorzoxazone were supplied by Sigma-Aldrich Co. (St Louis, MO, USA). Testosterone was obtained from International Laboratory Limited (San Bruno, CA, USA). 6β-hydroxytestosterone was purchased from BD Biosciences Co. (Woburn, MA, USA). Phenacetin, cortisone acetate, EB and EE were from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). NADPH was obtained from Roche Diagnostics GmbH (Mannheim, Germany). All other reagents were of HPLC or analytical grade.
Preparation of rat liver microsomes
Wistar rats (180 ± 20 g, male) were supplied by the Animal Experimental Center of Harbin Medical University (Harbin, China), which was fully accredited by the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of the Harbin Medical University (Permit Number: HMUIRB20120011), and the rats were handled in a manner that met all the recommendations formulated by the National Society for Medical Research and Guidelines for the Care and Use of Laboratory Animals. Rat liver microsomes were prepared from liver tissue by differential ultra-centrifugation , packed and stored at -80°C for further analysis. These operations were carried out in the ice. Protein concentrations of the microsomes were determined by the method of Bradford .
Cytochrome P450 probe substrate assays
Tolbutamide and 4-methyhydroxylation assay for CYP2C9
The incubation system of CYP2C9 in vitro contained phosphate buffer (100 mM, pH7.4), liver microsomal protein (0.5 mg · mL-1), MgCl2 (10 mM), tolbutamide (90 μM) and eleutherosides in a final volume of 200 μL. Pre-incubated 5 min, the reaction was initiated by adding NADPH (1 mM concentration in incubation) and the incubation systems were incubated at 37°C for 60 min. After incubation, 50 μL ice-cold acetonitrile was added to terminate the reaction, and phenacetin of a final concentration 20 μM was added as internal standard. With 5 min suspension, the mixture was centrifuged for 30 min at 12000 r · min-1. The supernatant of 20 μL was analyzed by the Waters HPLC system 2010 (Waters, USA, with 600 pump, 996PAD UV detector and Millipore Systems). Tolbutamide, 4-hydroxytolbutamide and phenacetin were separated on a Diamonsil C18 reverse phase column (5 μm, 4.6 mm × 200 mm). The column temperature was set to 35°C. The mobile phase, at a flow rate of 1 mL · min-1, consisted of methanol and 0.1% acetic acid (55:45, v/v). UV detection was at wavelength of 229 nm. The organic solvent which is at low concentration (≤0.5%) in all incubation systems wouldn’t affect the activity of enzymes. The yield of corresponding metabolites was calculated by referring to a standard curve constructed based on known concentrations of the pure metabolites.
Dextromethorphan and O-demethylation assay CYP2D6
Incubation conditions were the same as Section Tolbutamide and 4-methyhydroxylation assay for CYP2C9. The liver microsomal protein was 1.0 mg · mL-1 and tolbutamide was replaced by 25 μM dextromethorphan. Reactions were terminated by 80 μL ice-cold acetonitrile and internal standard phenacetin (final concentration of 50 μM) was added, the denatured protein was removed by centrifuged at 12000 r · min-1 for 30 min. The supernatant of 20 μL was injected into the HPLC system, with the mobile phase of methanol, water, phosphate and triethylamine (42:58:0.15:0.3, v/v/v/v) at a flow rate of 1 mL · min-1, detection was at wavelength of 280 nm.
Chlorzoxazone and 6-hydroxylation assay for CYP2E1
Each incubation mixture (200 μL) included liver microsomal protein (0.75 mg. mL-1), MgCl2 (10 mM) in 100 mM phosphate buffer (pH7.4) and 25 μM chlorzoxazone. With 5 min pre-incubation, all reactions were initiated by addition of NADPH (1 mM) and were carried out in 37°C water bath for 30 min, and then were stopped by addition of 150 μL ice-cold acetonitrile and internal standard (80 μM phenacetin). After centrifugation at 12000 r · min-1 for 30 min, 20 μL of the supernatant was injected into the HPLC system, and eluted with methanol–water (47:53) at a flow rate of 1.0 mL · min-1, UV absorbance was monitored at 287 nm.
Testosterone and 6β-hydroxylation assay for CYP3A4
Testosterone solution (in methanol, final concentration of 100 μM) was evaporated to dryness under nitrogen in 40°C water bath, then additional reagents were added to give a final incubation volume of 200 μL: liver microsomal protein (0.5 mg · mL-1) in 50 mM sodium phosphate buffer (pH7.4) and MgCl2 (10 mM). Following a 5 min pre-incubation, reactions were started with addition of NADPH (1 mM). Following 30 min incubations at 37°C, reactions were stopped with organic solution (280 μL ice-cold acetonitrile), and cortisone acetate was added as internal standard with final concentration of 12.5 μM. The mixture was centrifugated at 12000 r · min-1 for 30 min, and the supernatant of 20 μL was injected into the HPLC, with UV detection at 245 nm. Mobile phase consisted of methanol and water (65:35, v/v), and the flow rate was 1.0 mL · min-1.
Determination of Km and Vmax
The apparent Km (Michaelis constant) and Vmax (maximum reaction velocity) values were determined in a range of concentrations of probe drugs. The concentrations were as follows: tolbutamide 3.5~600.0 μM, dextromethorphan 3.5~400.0 μM, chlorzoxazone 5.0~300.0 μM, and testosterone 12.5~500.0 μM. The other incubation conditions were the same as Section Cytochrome P450 probe substrate assays.
Determination of effects of EB and EE on CYP450 activity
To evaluate whether EB and EE affect the activity of CYP450, the probe substrate reaction assays were performed with EB or EE at concentrations of 0, 2, 10, 25, 50, 150, 300 μM under the conditions described earlier, with triplicate incubations for each concentration. The concentrations of respective probe substrates were selected according to Km established in the enzyme kinetic assays described above. The IC50 values (concentration of inhibitor causing 50% inhibition of enzyme activity) were determined based on the concentration-inhibition curves.
Assay for enzymatic kinetic parameters
The exact inhibition constants (Ki values) were measured and the modes of inhibition were determined for the components exhibiting IC50 values of less than 200 μM. The Ki values were determined in a range of concentrations of probe substrates (approximately Km/2, Km, 2Km and 4Km) and different concentrations of EB (0, 100, 200, 300 μM) and EE(0, 100, 200, 300 μM). Dixon and Lineweaver-Burk plots and the second plots showed the data graphically for interpretation of inhibition mode. All experiments were separately performed in three times.
Enzymatic kinetic parameters for CYP450 in rat liver microsomes
The apparent Km values for tolbutamide 4-methyhydroxylation, dextro- methorphan O-demethylation, chlorzoxazone 6-hydroxylation and testosterone 6β-hydroxylation in rat liver microsomes were 94.80, 29.07, 30.42 and 103.81 μM, respectively. The Vmax values for tolbutamide 4-methyhydroxylation, dextromethorphan O-demethylation, chlorzoxazone 6-hydroxylation and testosterone 6β-hydroxylation in liver microsomes were 1.57, 0.28, 0.05 and 2.71 nmol/min/mg protein, respectively.
IC50 for EB and EE inhibition
Type of inhibition of CYP2E1 by EB and EE
The incubation experiment of liver microsomes is a generally used method for drug metabolism in vitro, which is recommended by the relevant guidelines of the United States . The liver microsomes consist of a variety of enzymes, and we chose tolbutamide, dextromethorphan, chlorzoxazone and testosterone, which are extensively used as probe substrates for CYP2C9, CYP2D6, CYP2E1 and CYP3A4 respectively in this study [22–25].
The present study addressed that EB and EE exhibited weak inhibition against rat CYP2C9, CYP2E1 activity, and no effect on CYP2D6 and CYP3A4 activity in rat liver microsomes in vitro. The IC50 values of EE and EB were 193.20 μM and 188.36 μM for CYP2E1, and 595.66 μM and 261.82 μM for CYP2C9, respectively. Kinetic analysis suggested that the inhibition of CYP2E1 by EB was best fit to a mixed-type with Ki value of 183.95 μM, while the inhibition of CYP2E1 by EE was also best fit to a mixed manner with Ki value of 171.63 μM. Consistently, Donovan et al assessed the influence of standardized extracts of ES on the activity of CYP2D6 and CYP3A4 in normal volunteers, and found that there were no statistically significant differences in the pharmacokinetic parameters determined by noncompartmental modeling, indicating that ES are unlikely to significantly affect CYP3A4 and CYP2D6 activities .
Our results suggest that EB and EE have inhibition effects on CYP2C9 and CYP2E1 in rat hepatic microsomes. Studies show that the extrapolation of CYP2E1 between species appears to be quite well, and rat seems to be best model for human in this respect . Based on the metabolic substrate studies, human CYP2C9 corresponds to rat CYP2C11, which has quite similar metabolic substrate with human CYP2C9 .
CYP2C9 metabolizes more than 10% of drugs clinically used, including antidepressants, hypoglycemics, angiotensin II blockers, non-steroidal anti-inflammatory drugs, S-warfarin, diclofenac, tolbutamide, glipizide, losartan, flurbiprofen, naproxen, ibuprofen, fluoxetine, sertraline, valproate, phenobarbital, phenytoin, fluvastatin, tamoxifen, etc [16, 28]. CYP2E1 also plays an important role in the metabolism of many commonly pharmaceuticals including nifedipine, erythromycin, acetaminophen, enflurane, ethanol and halothane [16, 28]. The inhibition can result in the increase of the plasma concentration and toxicity of concomitant drugs, especially for those with narrow therapeutic windows such as warfarin, phenobarbital and phenytoin. More attention should be paid when ES is used with these drugs concomitantly. However, further clinical investigation should be carried on to prove whether inhibitions by EB and EE on CYP2C9 or CYP2E1 may alter the pharmacokinetics of these drugs and increase their adverse drug reactions when they are co-administered with ES.
Previous studies have shown that concomitant administration of herbal preparations and pharmaceuticals may affect drug metabolism and significantly increase the risk of serious adverse reactions. For instance, the interaction between warfarin and St. John’s wort have been reported and the mechanism by which St. John’s wort activates CYP450 enzymes is possibly the most thoroughly researched idea . In addition, a number of the clinical relevance of herb interactions has been reported, touching on interactions of Salvia (Danshen), Flos carthami, Centella asiatica, Andrographis paniculata, Silybum marianum, Acorus calamus and Goldenseal with various CYP450 isoforms [30–36]. ES has been widely used as a traditional herbal medicine and popular herbal dietary supplements, and often co-administered with many other drugs [37–41], the present study may facilitate predicting possible herb-drug interactions when ES is used in combination with other drugs, and decrease the incidence of the CYP450-mediated interactions.
In conclusion, EB and EE inhibit CYP2C9 and CYP2E1 activity, but have no effect on CYP2D6 and CYP3A4 in rat liver microsomes in vitro. Both compounds show mixed-type inhibition of CYP2C9 and CYP2E1. The results suggest that both EB and EE could cause potential drug-drug interactions with drugs that are metabolized by CYP2C9 and CYP2E1. However, the inhibitory effects of EB and EE on both CYPs were relatively weak and further investigation is needed to evaluate whether the weak inhibitory effects of both compounds on the two CYP450 isoforms are clinically significant.
This work was financially supported by the National Natural Science Foundation of China (81173659) and Natural Science Foundation of Heilongjiang Province (D201044).
- Li T: Siberian ginseng. Horsetechnology. 2001, 11: 79-84.Google Scholar
- Pharmacopoeia Commission of People's Republic of China: Pharmacopoeia of the People’s Republic of China. 2010, Beijing: China Medical Science PressGoogle Scholar
- Drozd J, Sawicka T, Prosińska J: Estimation of humoral activity of Eleutherococcus senticosus. Acta Pol Pharm. 2002, 59 (5): 395-401.PubMedGoogle Scholar
- Han YM, Shi XQ: The research progress of Eleutherococcus senticosus. J Tradit Chin Med. 2011, 1: 54-55.Google Scholar
- Zhu YY, Wei XH: Determination of Eleutheroside B and Eleutheroside E in Acanthopanax senticosus by HPLC-PAD. Chin Pharm J. 2011, 16 (46): 1280-1282.Google Scholar
- Li C, Wang XY, Hu XW: Determination of eleutheroside B in antifatigue fraction of Acanthopanax senticosus by HPLC. Zhongguo Zhong Yao Za Zhi. 2008, 23 (33): 2800-2802.Google Scholar
- Lee S, Son D, Ryu J: Anti-oxidant activities of Acanthopanax senticosus stems and their lignan components. Arch Pharm Res. 2004, 1 (27): 106-110.View ArticleGoogle Scholar
- Díaz Lanza AM, Abad Martínez MJ, Fernández Matellano L, Recuero Carretero C: Lignan and phenylpropanoid glycosides from Phillyrea latifolia and their in vitro anti-inflammatory activity. Planta Med. 2001, 3 (67): 219-223.View ArticleGoogle Scholar
- Kapil A, Sharma S: Immunopotentiating compounds from Tinospora cordifolia. J Ethnopharmacol. 1997, 2 (58): 89-95.View ArticleGoogle Scholar
- Cho JY, Nam KH, Kim AR: In-vitro and in-vivo immunomodulatory effects of syringin. J Pharm Pharmacol. 2001, 9 (53): 1287-1294.View ArticleGoogle Scholar
- Niu HS, Liu IM, Cheng JT: Hypoglycemic effect of syringin from Eleutherococcus senticosus in streptozotocin-induced diabetic rats. Planta Med. 2008, 2 (74): 109-113.View ArticleGoogle Scholar
- Niu HS, Hsu FL, Liu IM, Cheng JT: Increase of beta-endorphin secretion by syringin, an active principle of Eleutherococcus senticosus, to produce antihyperglycemic action in type 1-like diabetic rats. Horm Metab Res. 2007, 12 (39): 894-898.View ArticleGoogle Scholar
- Tohda C, Ichimura M, Bai Y: Inhibitory effects of Eleutherococcus senticosus extracts on amyloid beta (25–35)-induced neuritic atrophy and synaptic loss. J Pharmacol Sci. 2008, 3 (107): 329-339.View ArticleGoogle Scholar
- Bai Y, Tohda C, Zhu S: Active components from Siberian ginseng (Eleutherococcus senticosus) for protection of amyloid beta (25–35)-induced neuritic atrophy in cultured rat cortical neurons. J Nat Med. 2011, 3–4 (65): 417-423.View ArticleGoogle Scholar
- Tokiwa T, Yamazaki T, Sakurai S: Anti-inflammatory effect of eleutheroside E from Acanthopanax senticosus. Foods Food Ingred J Jpn. 2006, 7 (211): 576-582.Google Scholar
- Huang LZ, Wei L, Zhao HF: The effect of Eleutheroside E on behavioral alterations in murine sleep deprivation stress model. Eur J Pharmacol. 2011, 2–3 (658): 150-155.View ArticleGoogle Scholar
- Huang LZ, Huang BK, Ye Q: Bioactivity-guided fractionation for anti-fatigue property of Acanthopanax senticosus. J Ethnopharmacol. 2011, 1 (133): 213-219.View ArticleGoogle Scholar
- Pelkonen O, Urpeinen MT, Hakkola J: Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008, 10 (82): 667-715.View ArticleGoogle Scholar
- Gibbson GG, Sheet P: Introduction to Drug Metabolism. 1994, London: Blackie Academic and ProfessionalGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 1–2 (72): 248-254.View ArticleGoogle Scholar
- Bjornsson TD, Callaghan JT, Einolf HJ: The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003, 7 (31): 815-832.View ArticleGoogle Scholar
- Xia CH, Sun JG, Wang GJ: Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. Planta Med. 2009, 3 (76): 245-250.Google Scholar
- Babbar S, Chanda S, Bley K: Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica. 2010, 12 (40): 807-816.View ArticleGoogle Scholar
- Fayer JL, Petullo DM, Ring BJ: A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro. J Pharmacol Toxicol Methods. 2002, 2 (46): 117-123.Google Scholar
- Khojasteh SC, Prabhu S, Kenny JR: Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011, 1 (36): 11-16.Google Scholar
- Donovan JL, DeVane CL, Chavin KD: Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos. 2003, 5 (31): 519-522.View ArticleGoogle Scholar
- Martignoni M, Groothuis GM, de Kanter R: Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006, 2 (6): 875-894. 10.1517/17425255.2.6.875.View ArticlePubMedGoogle Scholar
- Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, Pasanen M: Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica. 2007, 37 (12): 1367-1377. 10.1080/00498250701658312.View ArticlePubMedGoogle Scholar
- Obach RS: Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort. an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 2000, 1 (294): 88-95.Google Scholar
- Winitthana T, Niwattisaiwong N, Patarapanich C: In vitro inhibitory effects of asiaticoside and madecassoside on human cytochrome P450. Toxicol In Vitro. 2011, 4 (25): 890-896.View ArticleGoogle Scholar
- Qiu F, Zhang R, Sun J: Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos. 2008, 7 (36): 1308-1314.View ArticleGoogle Scholar
- Chatterjee P, Franklin MR: Human cytochrome p450 inhibition and metabolic- intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003, 11 (31): 1391-1397.View ArticleGoogle Scholar
- Pekthong D, Martin H, Abadie C: Differential inhibition of rat and human hepatic cytochrome P450 by Andrographis paniculata extract and andrographolide. Ethnopharmacol. 2008, 3 (115): 432-440.View ArticleGoogle Scholar
- Pandit S, Mukherjee PK, Ponnusankar S: Metabolism mediated interaction of alpha-asarone and Acorus calamus with CYP3A4 and CYP2D6. Fitoterapia. 2011, 3 (82): 369-374.View ArticleGoogle Scholar
- Liu G, Liu Y, Liu R: Effects of Flos carthami on CYP2D6 and on the Pharmacokinetics of Metoprolol in Rats. Evid Based Complement Alternat Med. 2011, 207076-doi:10.1155/2011/207076Google Scholar
- Doehmer J, Weiss G, McGregor GP, Appel K: Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro. 2011, 1 (25): 21-27.View ArticleGoogle Scholar
- Cao Y, Yan X: Study on effects of 36 cases of propofol combined with Acanthopanax Injection for the treatment of insomnia patients. Zhongguo Shi Yong Yi Yao. 2011, 14 (6): 135-Google Scholar
- Chu X, Liu D: 60 cases of Acanthopanax injection combined with choline injection in the treatment of cervical vertigo. J Tradit Chin Med. 2011, 10 (20): 1699-1700.Google Scholar
- Gai Y, Zhang T: Clinical study on the effect of Acanthopanax Injection combined with Liposomal Alprostadil in the treatment of stage-IV diabetic nephropathy. J Tradit Chin Med. 2011, 4 (18): 535-537.Google Scholar
- Du Y: Analysis of literature of 228 cases of adverse drug reactions caused by Acanthopanax Senticosus injection. Zhongguo Lin Chuang Xin Yi Xue. 2011, 10 (4): 946-948.Google Scholar
- Hu J, Shang H, Li J, Zhang L: 521 cases of adverse drug reactions of Eleutherococcus senticosus Injection based on 944 studies. J Evid Based Med. 2010, 2 (10): 182-188.Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/1/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.